BrainSee

BrainSee is an artificial intelligence-powered prognostic tool that analyzes volumetric features from brain MRIs and cognitive scores to predict the five-year likelihood of progression from amnestic mild cognitive impairment to Alzheimer's dementia. Its methodology aims to provide clinicians with a non-invasive, quantitative risk assessment to aid in early identification and management of high-risk patients.

BrainSee is a prognostic software tool developed to predict the likelihood of patients diagnosed with amnestic mild cognitive impairment (aMCI) progressing to Alzheimer’s dementia within a five-year timeframe. The system functions by requiring clinicians to upload a standard 3T brain MRI scan along with concise cognitive assessment scores for the patient. An artificial intelligence algorithm then processes this data, specifically analyzing volumetric features extracted from the MRI, such as hippocampal volume and cortical thickness, in conjunction with the provided cognitive metrics. The output is a similarity score, ranging from 0 to 100, which indicates the patient's neuro-cognitive profile resemblance to individuals known to convert to Alzheimer's dementia versus those who remain stable. The tool's predictive capabilities have been validated through studies on independent cohorts, demonstrating a sensitivity of approximately 71% and a specificity of around 83%. By leveraging machine learning techniques, BrainSee provides a non-invasive method for assessing the risk of progression. This assists neurologists and other relevant healthcare professionals in the early identification of aMCI patients who are at a higher risk of developing Alzheimer's dementia. Such early identification can facilitate more timely consideration for targeted therapeutic interventions, lifestyle modifications, or enrollment in pertinent clinical trials aimed at slowing or preventing disease progression.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the AI algorithm precisely weight the volumetric MRI features against the cognitive scores in its calculation of the similarity score?; What specific cognitive tests are utilized for the 'concise cognitive scores', and how sensitive is the model to variations in these scores?; Beyond hippocampal volume and cortical thickness, what other specific neuroanatomical features are analyzed by the AI, and what is their relative prognostic contribution?; How does BrainSee's performance compare to other established biomarkers or prognostic methods for predicting progression from aMCI to Alzheimer's dementia?; What are the characteristics of the independent cohorts used for validation, and how might factors like age, education, or genetic predispositions influence BrainSee's predictive accuracy across diverse populations?